EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease

Michael G Zaki iD, Elisabet Jakova, Mahboubeh Pordeli, Elina Setork, Changiz Taghibiglou iD, Francisco S Cayabyab iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Michael G Zaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Neuroscience Research Cluster, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canad…. Hauptthemen laut MEDLINE: Purines, Adenosine A2 Receptor Antagonists, Parkinson Disease, Brain Ischemia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Stroke Foundation of Canada, Saskatchewan Health Research Foundation Collaborative Innovation and Development Grant, Natural Sciences and Engineering Research Council of Canada Discovery Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Stroke, the third leading cause of death worldwide, is a major cause of functional disability. Cerebral ischemia causes a rapid elevation of adenosine, the main neuromodulator in the brain. The inhibition of adenosine A2A receptors (A2ARs) has been introduced as a potential target in neurodegenerative disorders involving extracellular adenosine elevation. Istradefylline, a selective A2AR antagonist, has been approved for Parkinson’s disease (PD) adjunctive therapy and showed neuroprotective effects in PD and Alzheimer’s disease. However, the role of A2ARs in post-stroke neuronal damage and behavioral deficits remains unclear. We recently showed that A2AR antagonism prevented the adenosine-induced post-hypoxia synaptic potentiation of glutamatergic neurotransmission following the hypoxia/reperfusion of hippocampal slices. Here, we investigated the potential neuroprotective effects of istradefylline in male Sprague-Dawley rats subjected to pial vessel disruption (PVD) used to model a small-vessel stroke. Rats were treated with either a vehicle control or istradefylline (3 mg/kg i.p.) following PVD surgery for three days. Istradefylline administration prevented anxiety and depressive-like behaviors caused by PVD stroke. In addition, istradefylline significantly attenuated ischemia-induced cognitive impairment and motor deficits. Moreover, istradefylline markedly reduced hippocampal neurodegeneration, as well as GFAP/Iba-1, TNF-α, nNOS, and iNOS levels after PVD, but prevented the downregulation of anti-inflammatory markers TGF-β1 and IL-4. Together, these results suggest a molecular link between stroke and PD and that the anti-PD drug istradefylline displays translational potential for drug repurposing as a neuroprotective agent for cerebral ischemic damage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PurinesAdenosine A2 Receptor AntagonistsParkinson DiseaseBrain IschemiaNeuroinflammatory DiseasesStrokeAnimalsMaleRatsRats, Sprague-DawleyNeuroprotective AgentsReceptor, Adenosine A2ASignal TransductionBehavior, AnimalAdenosineDisease Models, Animal

Stichwörter der Autor:innen

adenosine A1 receptoradenosine A2A receptorfEPSPglutamate excitotoxicityischemic strokeistradefyllinestroke model

Substanzen

istradefyllinePurinesAdenosine A2 Receptor AntagonistsNeuroprotective AgentsReceptor, Adenosine A2AAdenosine

Autor:innen und Institutionen

  • Department of Surgery, Neuroscience Research Cluster, College of Medicine, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.
  • Department of Anatomy, Physiology and Pharmacology, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada.

ORCID-Profile: Michael G Zaki, Changiz Taghibiglou, Francisco S Cayabyab

Förderung

  • Heart and Stroke Foundation of Canada
  • Saskatchewan Health Research Foundation Collaborative Innovation and Development Grant
  • Natural Sciences and Engineering Research Council of Canada Discovery Grant
  • Natural Sciences and Engineering Research Council of Canada
  • University of Saskatchewan

Zitieren

APA

Zaki, M. G., Jakova, E., Pordeli, M., Setork, E., Taghibiglou, C., & Cayabyab, F. S. (2025). The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125680

Vancouver

Zaki MG, Jakova E, Pordeli M, Setork E, Taghibiglou C, Cayabyab FS. The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125680

BibTeX
@article{Zaki2025,
  author = {Zaki, Michael G and Jakova, Elisabet and Pordeli, Mahboubeh and Setork, Elina and Taghibiglou, Changiz and Cayabyab, Francisco S},
  title = {The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson’s Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125680}
}
Kostenlos starten →